These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37311751)

  • 21. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.
    Puleo F; Nicolle R; Blum Y; Cros J; Marisa L; Demetter P; Quertinmont E; Svrcek M; Elarouci N; Iovanna J; Franchimont D; Verset L; Galdon MG; Devière J; de Reyniès A; Laurent-Puig P; Van Laethem JL; Bachet JB; Maréchal R
    Gastroenterology; 2018 Dec; 155(6):1999-2013.e3. PubMed ID: 30165049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
    Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
    PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma.
    Salinas-Miranda E; Healy GM; Grünwald B; Jain R; Deniffel D; O'Kane GM; Grant R; Wilson J; Knox J; Gallinger S; Fischer S; Khokha R; Haider MA
    Eur Radiol; 2022 Oct; 32(10):6712-6722. PubMed ID: 36006427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer.
    Dings MPG; Manoukian P; Waasdorp C; Quik JSE; Strijker M; Lodestijn SC; van Neerven SM; Moreno LF; de Oliveira RL; Bonsing BA; Bruno MJ; Busch OR; Doukas M; van Eijck CH; Mohammad NH; de Hingh IH; Molenaar QI; Besselink MG; Vermeulen L; Medema JP; van Laarhoven HWM; Bijlsma MF
    Int J Cancer; 2023 Feb; 152(3):511-523. PubMed ID: 36069222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients.
    Ju J; Wismans LV; Mustafa DAM; Reinders MJT; van Eijck CHJ; Stubbs AP; Li Y
    iScience; 2021 Dec; 24(12):103415. PubMed ID: 34901786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma.
    Thompson CM; Cannon A; West S; Ghersi D; Atri P; Bhatia R; Smith L; Rachagani S; Wichman C; Kumar S; Batra SK
    Clin Cancer Res; 2021 Dec; 27(24):6787-6799. PubMed ID: 34615717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Epithelial-stromal interactions in pancreatic adenocarcinoma: the role of stroma in disease progression].
    Kuznetsova AV; Popova OP; Astakhov DA; Ivanov YV; Panchenkov DN; Ivanov AA
    Arkh Patol; 2022; 84(5):65-70. PubMed ID: 36178225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
    Nicolle R; Gayet O; Duconseil P; Vanbrugghe C; Roques J; Bigonnet M; Blum Y; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Giovannini M; Grandval P; Dahan L; Moutardier V; Gilabert M; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
    Ann Oncol; 2021 Feb; 32(2):250-260. PubMed ID: 33188873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
    J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components.
    Zhao S; Nicolle R; Augustin J; Svrcek M; de Mestier L; Le Corre D; Pietrasz D; Caliez O; Cros J; Laurent-Puig P; Bachet JB
    Clin Cancer Res; 2021 Dec; 27(23):6491-6499. PubMed ID: 34518308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma.
    Yan B; Liu L; Zhao L; Hinz U; Luo Y; An X; Gladkich J; de la Torre C; Huang Z; Schrapel D; Gross W; Fortunato F; Schaefer M; Gaida MM; Herr I
    Matrix Biol; 2022 Dec; 114():84-107. PubMed ID: 36375776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DEMoS: a deep learning-based ensemble approach for predicting the molecular subtypes of gastric adenocarcinomas from histopathological images.
    Wang Y; Hu C; Kwok T; Bain CA; Xue X; Gasser RB; Webb GI; Boussioutas A; Shen X; Daly RJ; Song J
    Bioinformatics; 2022 Sep; 38(17):4206-4213. PubMed ID: 35801909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype.
    Juiz N; Elkaoutari A; Bigonnet M; Gayet O; Roques J; Nicolle R; Iovanna J; Dusetti N
    FASEB J; 2020 Sep; 34(9):12214-12228. PubMed ID: 32686876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The WNT5A/ROR2 signaling pathway in pancreatic ductal adenocarcinoma (PDAC).
    Remtisch L; Wiltberger G; Schierle K; Yousef M; Thieme R; Jansen Winkeln B; Wittekind C; Gockel I; Lyros O
    J BUON; 2021; 26(4):1595-1606. PubMed ID: 34565024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation and comparison of the molecular classifications of pancreatic carcinomas.
    Birnbaum DJ; Finetti P; Birnbaum D; Mamessier E; Bertucci F
    Mol Cancer; 2017 Nov; 16(1):168. PubMed ID: 29110659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 37. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 38. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy.
    Naito Y; Tsuneki M; Fukushima N; Koga Y; Higashi M; Notohara K; Aishima S; Ohike N; Tajiri T; Yamaguchi H; Fukumura Y; Kojima M; Hirabayashi K; Hamada Y; Norose T; Kai K; Omori Y; Sukeda A; Noguchi H; Uchino K; Itakura J; Okabe Y; Yamada Y; Akiba J; Kanavati F; Oda Y; Furukawa T; Yano H
    Sci Rep; 2021 Apr; 11(1):8454. PubMed ID: 33875703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma.
    Melendez-Zajgla J; Maldonado V
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.